| Literature DB >> 35407122 |
Rao Wu1, Chen Chen1, Xiaoying Zhang1,2,3.
Abstract
The proteomic profiles of Silky fowl egg yolk (SFEY) and Leghorn egg yolk (LEY) were analyzed by bottom-up label-free liquid chromatography-tandem mass spectrometry (LC-MS/MS). From a total of 186 identified proteins, 26 proteins were found significantly differentially abundant between two yolks, of which, 19 were up-regulated and 7 were down-regulated in SFEY, particularly, vitelline membrane outer layer protein 1, transthyretin and ovoinhibitor were up-regulated by 26, 25, and 16 times, respectively. In addition, there were 57 and 6 unique proteins in SFEY and LEY, respectively. Gene Ontology (GO) revealed SFEY contained relatively more abundant protease inhibitors and coagulation-related proteins. Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis revealed differentially abundant proteins in SFEY may be actively involved in the regulation of the neuroactive ligand-receptor interaction pathway. This study provides a theoretical basis for the understanding of proteomic and biological differences between these two yolks and can guide for further exploration of nutritional and biomedical use of Silky fowl egg.Entities:
Keywords: egg yolk; hemostasis; label-free proteomic analysis; neuroactive ligand–receptor interaction; ovoinhibitor; silky fowl (black-bone chicken); transthyretin
Year: 2022 PMID: 35407122 PMCID: PMC8997978 DOI: 10.3390/foods11071035
Source DB: PubMed Journal: Foods ISSN: 2304-8158
List of significantly differentially abundant proteins in SFEY versus LEY.
| Protein Name | Accessions | Unique Peptides | SFEY/LEY Fold Changes | GO Terms | |
|---|---|---|---|---|---|
| Vitelline membrane outer layer protein 1 | P41366 | 1 | 26.452 ↑ | 0.007 | Extracellular region |
| Transthyretin | A0A1L1RWR0 | 3 | 24.708 ↑ | 0.023 | Cellular lipid metabolic process; hormone metabolic process |
| Alpha-2-macroglobulin-like 4 | F1NK40 | 30 | 17.041 ↑ | 0.027 | Molecular function regulator; enzyme regulator activity |
| Ovoinhibitor | P10184 | 18 | 15.797 ↑ | <0.001 | Regulation of proteolysis; peptidase regulator activity; serine-type endopeptidase inhibitor activity |
| Ig-like domain-containing protein | A0A3Q3AN21; A0A3Q2UGI5; A0A3Q2TZD6; A2N890; A2N888 | 2 | 11.154 ↑ | 0.009 | Immune system process |
| C4a anaphylatoxin | Q076D6; D4QB02; D4QB00 | 2 | 8.493 ↑ | <0.001 | Response to stress; proteolysis; peptidase regulator activity |
| Apolipoprotein A-I | P08250 | 10 | 7.843 ↑ | 0.006 | Response to stress; enzyme regulator activity |
| Ig-like domain-containing protein | A0A3Q2U474 | 3 | 7.608 ↑ | <0.001 | Immune system process |
| Ig-like domain-containing protein | A0A1D5PAQ0; A0A3Q2UGD4; A0A3Q2U2P6 | 2 | 6.610 ↑ | 0.003 | Immune system process |
| Avidin-related protein 6-like | A0A3Q2UD25 | 5 | 5.915 ↑ | 0.044 | Amide binding; biotin binding |
| Complement component 3 | A0A1D5P9F9; A0A1D5PWR4; A0A1D5PFG3; A0A1D5PQ85; A6N9E0; Q2MV09; Q6PPA9 | 10 | 5.416 ↑ | <0.001 | Regulation of response to external stimulus; regulation of proteolysis; peptidase regulator activity; endopeptidase regulator activity |
| Kininogen 1 | A0A1L1RNR4 | 5 | 5.060 ↑ | <0.001 | Hemostasis; blood coagulation; peptidase regulator activity |
| Complement factor H | A0A3Q2TRY3A0A3 | 25 | 4.301 ↑ | 0.042 | Immune effector process; protein activation cascade |
| C4a anaphylatoxin | A0A290WNG2 | 3 | 3.694 ↑ | 0.035 | Response to stress; proteolysis; peptidase regulator activity |
| Prothrombin | Q91001; F1NXV6 | 11 | 3.534 ↑ | 0.006 | Hemostasis; blood coagulation; serine-type endopeptidase activity |
| Ig-like domain-containing protein | A0A3Q2U343 | 1 | 2.831 ↑ | 0.018 | Immune system process |
| Plasminogen | F1NWX6; Q7LZF3 | 24 | 2.816 ↑ | 0.002 | Hemostasis; blood coagulation; serine-type endopeptidase activity |
| PIT 54 | Q98TD1; A0A1L1S0P1 | 13 | 2.651 ↑ | <0.001 | Scavenger receptor activity |
| Fibrinogen alpha chain | P14448; F1P4V1 | 13 | 2.527 ↑ | 0.043 | Hemostasis; blood coagulation; response to stress |
| Ig-like domain-containing protein | A0A3Q2UAA5 | 7 | 0.413 ↓ | <0.001 | Immune system process |
| Dishevelled binding antagonist of beta catenin 2 | A0A1D5NWD7 | 1 | 0.380 ↓ | 0.002 | Negative regulation of cell adhesion; regulation of response to stimulus; tube development |
| Ig-like domain-containing protein | A0A3Q2U9M3 | 2 | 0.373 ↓ | 0.008 | Immune system process |
| Apovitellenin-1 | P02659 | 7 | 0.248 ↓ | <0.001 | Lipid metabolic process; enzyme inhibitor activity |
| Ovalbumin (Fragment) | A0A2H4Y866; A0A2H4Y8E8; P0102; A0A2H4Y8S8; A0A2H4Y8R9; A0A2H4Y8R6; A0A2H4Y8R1 | 6 | 0.233 ↓ | 0.001 | Extracellular region |
| Complement component 7 | F1DQG4; E1C6U2 | 17 | 0.19 ↓ | <0.001 | Immune effector process; protein activation cascade |
| Avidin | E1BTQ4; A0A3Q2U4N2; A0A3Q2UC51 | 3 | 0.113 ↓ | 0.003 | Amide binding; biotin binding |
↑, up-regulation; ↓, down-regulation.
Figure 1Profiles of differently expressed proteins identified in SFEY and LEY using cluster analysis. A total of 26 proteins were observed with significantly difference. Three biological replicates of SFEY and LEY were presented separately. Red and blue: significantly up-regulated and down-regulated proteins, respectively; gray: no quantitation information.
Figure 2Domain analysis and GO annotation of differentially abundant proteins. Panels (A,C) represent domain and GO annotation statistics of differentially abundant proteins, respectively. Vertical axis represents domain and GO term; horizontal axis represents the number of differentially abundant proteins corresponding to the domain and GO term. Panel (B) represents domain enrichment of differentially abundant proteins. Panels (D–F) represent GO function enrichment of differentially abundant proteins for biological processes, molecular functions and cellular components, respectively. Vertical axis represents different domain or GO function category; horizontal axis represents the enrichment factor (≤1; numbers of differentially abundant proteins associated with a domain or GO term/numbers of characterized proteins corresponding to the domain and GO term); the colors of the bubble indicate the significance of the enriched domain or GO terms; and the color gradient from green to red represents the increasing significant difference.
Figure 3KEGG annotations and pathway enrichment analysis results. Panel (A) represents KEGG pathway annotate results of differentially abundant proteins. The vertical axis represents KEGG pathways and the horizontal axis represents the number of differentially abundant proteins involved in each pathway. Panel (B) represents KEGG pathway enrichment results of differentially abundant proteins. The vertical axis represents different KEGG pathways and the horizontal axis represents the enrichment factor (≤1; numbers of differentially abundant proteins associated with a KEGG pathway/numbers of characterized proteins corresponding to the pathway). The colors of the bubble indicate the significance of the enriched KEGG pathway, and the color gradient from green to red represents the increasing significant difference.
Figure 4(A) Enriched plasminogen, prothrombin and angiotensin 1–10 involved in the metabolic pathway of neuroactive ligand–receptor. The up-regulated proteins in the pathways were summarized. The highly expressed AGT and PARL in SFEY are involved in the metabolic pathway of neuroactive. Square frames represent proteins in the metabolic pathway. Round frames represent small molecular metabolites. The boxes in red indicate the up-regulated proteins. HTR, 5-hydroxytryptamine receptor 2; TAR, trace amine-associated receptor; AGT, angiotensinogen Ⅱ, Ⅲ; AGTR, angiotensin II receptor type 1; NPFF, neuropeptide FF-amide peptide; NPFFR, neuropeptide FF receptor 1; NPY, neuropeptide Y; NPYR, neuropeptide Y receptor; AVP, arginine vasopressin; AVPR, arginine vasopressin receptor 2; PAL, proteinase-activated like; PAR, proteinase-activated receptor; PRLH, prolactin-releasing-like hormone; PRLHR, prolactin-releasing hormone receptor. (B) Interaction networks of differentially abundant proteins. Circle nodes: differentially abundant proteins (red: up-regulation; circle size: degree of connectivity of the protein, namely, the number of proteins that directly interact with a protein); lines: protein–protein interactions.
List of domains and GO categories contained in ProteinsVar.
| Domain Name | GO Category | ProteinsVar | ProteinsVar Name |
|---|---|---|---|
| Serpin (serine protease inhibitor) | / | 8 | SERPIN domain-containing protein (A0A1D5PI58, E1C7T1, F1NAR5), Heparin cofactor II (Fragment), Ovalbumin-related protein Y, Angiotensin 1–10, Antithrombin-III (Fragment), Ovalbumin (A0A1D5PI58) |
| Alpha-2-macroglobulin family | / | 6 | Alpha-2-macroglobulin-like 4, C4a anaphylatoxin (Q07606, A0A290WNG2), Complement component 3, Complement component 5, Uncharacterized protein (A0A3Q3B2L3) |
| Alpha-2-macroglobulin family N-terminal region | / | 6 | Alpha-2-macroglobulin-like 4, C4a anaphylatoxin (Q07606, A0A290WNG2), Complement component 3, Complement component 5, Uncharacterized protein (A0A3Q3B2L3) |
| Anaphylotoxin-like domain | / | 5 | C4a anaphylatoxin (Q07606, A0A290WNG2), Complement component 3, Complement component 5, Fibulin-1 |
| Vitamin K-dependent carboxylation/ | / | 4 | Prothrombin, Vitamin K-dependent protein S, Anticoagulant protein C, Coagulation factor X |
| MG2 domain | / | 5 | Alpha-2-macroglobulin-like 4, C4a anaphylatoxin (Q07606, A0A290WNG2), Complement component 3, Complement component 5 |
| Kringle domain | / | 3 | Prothrombin, Plasminogen, Coagulation factor XII |
| Trypsin | / | 5 | Prothrombin, Plasminogen, Coagulation factor XII, Anticoagulant protein C, Coagulation factor X |
| A-macroglobulin receptor | / | 5 | Alpha-2-macroglobulin-like 4, C4a anaphylatoxin (Q07606, A0A290WNG2), Complement component 3, Complement component 5 |
| A-macroglobulin complement component | / | 5 | Alpha-2-macroglobulin-like 4, C4a anaphylatoxin (Q07606, A0A290WNG2), Complement component 3, Complement component 5 |
| / | Peptidase regulator activity, | 15 | SERPIN domain-containing protein (E1C7T1, F1NAR5), Heparin cofactor II (Fragment), Ovalbumin-related protein Y, Angiotensin 1–10, Antithrombin-III (Fragment), Ovoinhibitor, Alpha-2-macroglobulin-like 4, C4a anaphylatoxin (Q07606, A0A290WNG2), Complement component 3, Complement component 5, Kininogen-1, Inter-alpha inhibitor heavy chain 2, Uncharacterized protein (A0A3Q3B2L3) |
| / | Serine-type endopeptidase activity. | 5 | Prothrombin, Plasminogen, Coagulation factor XII, Anticoagulant protein C, Coagulation factor X |
| / | Hemostasis, coagulation, blood coagulation, regulation of body fluid levels, wound healing, response to wounding. | 12 | Prothrombin, Plasminogen, Coagulation factor XII, Anticoagulant protein C, Coagulation factor X, Vitamin K-dependent protein S, Fibrinogen alpha chain, Kininogen-1, Peptidase_M14 domain-containing protein, SERPIN domain-containing protein (F1NAR5), Antithrombin-III (Fragment), Heparin cofactor II (Fragment) |
| / | Regulation of response to wounding, regulation of wound healing, regulation of blood coagulation, regulation of coagulation, regulation of hemostasis | 6 | Kininogen-1, Vitamin K-dependent protein S, Plasminogen, Peptidase_M14 domain-containing protein, SERPIN domain-containing protein (F1NAR5), Antithrombin-III (Fragment) |
| / | Extracellular region, | 30 | SERPIN domain-containing protein (A0A1D5PI58, E1C7T1, F1NAR5), Heparin cofactor II (Fragment), Ovalbumin-related protein Y, Angiotensin 1–10, Antithrombin-III (Fragment), Ovalbumin (A0A1D5PI58), Alpha-2-macroglobulin-like 4, C4a anaphylatoxin (Q07606, A0A290WNG2), Complement component 3, Complement component 5, Fibrinogen alpha chain, 60 kDa heat shock protein, Apovitellenin-1, Apolipoprotein A-I, Gallinacin-9, Ceruloplasmin, Glycosyl-phosphatidylinositol-specific phospholipase D, Kininogen-1, Transthyretin, Alpha-1-acid glycoprotein, Coagulation factor XII, Peptidase_M14 domain-containing protein, Ovoinhibitor, Coagulation factor X, 14-3-3 protein zeta, Vitelline membrane outer layer protein 1 |
ProteinsVar, unique and differently expressed proteins in two yolks.